Show simple item record

dc.contributor.authorGonzalez-Gomez, Pilar 
dc.contributor.authorAnselmo, Nilson Praia
dc.contributor.authorMira, Helena
dc.date.accessioned2020-04-13T12:47:51Z
dc.date.available2020-04-13T12:47:51Z
dc.date.issued2014
dc.identifier.citationBiomed Res Int. 2014;2014:549742.es_ES
dc.identifier.issn2314-6133es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9532
dc.description.abstractAstrocytic glioma is the most common brain tumor. The glioma initiating cell (GIC) fraction of the tumor is considered as highly chemoresistant, suggesting that GICs are responsible for glioma relapse. A potential treatment for glioma is to induce differentiation of GICs to a more benign and/or druggable cell type. Given BMPs are among the most potent inducers of GIC differentiation, they have been considered as noncytotoxic therapeutic compounds that may be of use to prevent growth and recurrence of glioma. We herein summarize advances made in the understanding of the role of BMP signaling in astrocytic glioma, with a particular emphasis on the effects exerted on GICs. We discuss the prognostic value of BMP signaling components and the implications of BMPs in the differentiation of GICs and in their sensitization to alkylating drugs and oncolytic therapy/chemotherapy. This mechanistic insight may provide new opportunities for therapeutic intervention of brain cancer.es_ES
dc.description.sponsorshipThis study was supported by grants from Ministerio de Sanidad y Consumo (MSC; Fondo de Investigación Sanitaria, PI12/101) and Comunidad de Madrid (S2010/BMD-2336) to Helena Mira. They are grateful to Marcos García-Fuentes and Pilar Sánchez for sharing unpublished results. Nilson Praia Anselmo is a recipient of a postdoctoral fellowship from “Ciência sem Fronteiras”—Brazil Scientific Mobility Program/CAPES.es_ES
dc.language.isoenges_ES
dc.publisherHindawi es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshAstrocytoma es_ES
dc.subject.meshBiomarkers, Tumor es_ES
dc.subject.meshBone Morphogenetic Proteins es_ES
dc.subject.meshHumans es_ES
dc.subject.meshNeoplasm Proteins es_ES
dc.subject.meshNeoplastic Stem Cells es_ES
dc.subject.meshPrognosis es_ES
dc.titleBMPs as therapeutic targets and biomarkers in astrocytic gliomaes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID24877113es_ES
dc.format.volume2014es_ES
dc.format.page549742es_ES
dc.identifier.doi10.1155/2014/549742es_ES
dc.contributor.funderComunidad de Madrid (España) 
dc.contributor.funderFundación Pedro Barrié de la Maza
dc.description.peerreviewedes_ES
dc.identifier.e-issn2314-6141es_ES
dc.relation.publisherversionhttps://doi.org/10.1155/2014/549742es_ES
dc.identifier.journalBioMed research internationales_ES
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)es_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI12/101es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/S2010/BMD-2336es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional